Gherardini Lisa, Sharma Ankush, Capobianco Enrico, Cinti Caterina
Center for Computational Science (CCS), University of Miami, Miami, FL, USA.
Curr Pharm Biotechnol. 2016;17(10):856-65. doi: 10.2174/1381612822666160527154757.
Recent pan-cancer studies have shown the importance of coupling DNA methylation patterns with transcriptome profiles to reveal tumor subgroups with clinically relevant distinct characteristics. While the coupling patterns remain in most cases matter for further study and/or interpretation, it is emerging that all associations between epigenetic changes and specific cancer histotypes can facilitate the development of novel epidrugs. In particular, together with chemotherapy and chemoprevention of cancer, these epidrugs will target specific enzymes involved in the complex regulation of gene expression. This perspective surveys recent cancer epigenetic findings on target drugs and therapeutic strategies, and focuses on the epigenetic modifications that can reverse a stable differentiated state of adult cell towards neoplastic phenotypes. The relevance of such developments may thus pave the way for patient's customized personalized therapies.
近期的泛癌研究表明，将DNA甲基化模式与转录组图谱相结合对于揭示具有临床相关独特特征的肿瘤亚组非常重要。虽然在大多数情况下，这种耦合模式对于进一步研究和/或解释仍然很重要，但越来越多的证据表明，表观遗传变化与特定癌症组织学类型之间的所有关联都有助于新型表观遗传药物的开发。特别是，与癌症的化疗和化学预防一起，这些表观遗传药物将靶向参与基因表达复杂调控的特定酶。本综述探讨了近期关于靶向药物和治疗策略的癌症表观遗传学研究结果，并重点关注能够使成年细胞从稳定的分化状态逆转为肿瘤表型的表观遗传修饰。因此，这些进展的相关性可能为患者定制个性化治疗铺平道路。
